💊 İlaçlar A-Z 🧬 Hedefler 🛠 Araçlar 📚 Rehberler
Tüm İlaçlar İlaç Sınıfları Terapötik Alanlar Yan Etkiler
Rehberler Sözlük Zaman Çizelgesi
Karşılaştırmalar İlaç Yolculukları İlaç Aileleri
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Ranitidine Hydrochloride

CHEMBL2110372 Phase 4 Onaylandı Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
350.9 g/mol
LogP
—
Phase
4

The hydrochloride salt form of ranitidine used to reduce stomach acid and treat conditions like peptic ulcers and gastroesophageal reflux disease. This formulation was widely prescribed before safety concerns led to its market withdrawal.

Moleküler Ağırlık

350,8700 g/mol

TPSA

112,00 Ų

Terapötik Alanlar

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Chronic Obstructive Pulmonary Disease Gastroesophageal Reflux Disease Multiple Sclerosis Stroke Obesity Lymphoma Hypertension Breast Cancer Heart Failure Prostate Cancer Colorectal Cancer Leukemia

Etki Mekanizması

Competitive H2 receptor antagonist.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Competitive H2 receptor antagonist.

2D Yapı

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1.Cl

                

                

                
                

                    
InChI

                    
InChI=1S/C13H22N4O3S.ClH/c1-14-13(9-17(18)19)15-6-7-21-10-12-5-4-11(20-12)8-16(2)3;/h4-5,9,14-15H,6-8,10H2,1-3H3;1H

                

                

                

                    
                    

                        
Molecular Formula

                        
C13H23ClN4O3S

                    

                    
                    

                        
HBD / HBA

                        
3 / 7

                    

                    
                    

                        
Döndürülebilir Bağlar

                        
9

                    

                    
                    
                    

                        
Ağır Atomlar

                        
22

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Sıkça Sorulan Sorular

                

                    
                    

                        
                        

                            
The hydrochloride salt form of ranitidine used to reduce stomach acid and treat conditions like peptic ulcers and gastroesophageal reflux disease. This formulation was widely prescribed before safety concerns led to its market withdrawal.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Competitive H2 receptor antagonist.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Ranitidine Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL2110372.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 3033332.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Tıbbi Sorumluluk Reddi

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.